Shandong Buchang Pharmaceutical Co., Ltd (“Buchang Pharmaceutical”for short) was established in 2001 and completed the shareholding system reform in 2012. In July 2016, the company passed the IPO review by China Securities Regulatory Commission and was successfully listed on November 18, 2016.
In the past 19 years’ development, Buchang Pharmaceutical has established a clear development strategy, which is “Focusing on major diseases & Cultivating large varieties”. The company patented traditional Chinese medicines as the core and committed to the modernization of Chinese medicines. It fully plays to the important role of Chinese medicine in the field of “serious and chronic diseases” of cardiovascular and cerebrovascular diseases. The company formed a foothold in the cardiovascular market and created a three- dimensional pattern of product system by covering the advantages of traditional Chinese medicine field; focusing kinds of serious illness; and cultivating large variety of products.
